Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRĪ± Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.

Cheng X, Li J, Tanaka K, Majumder U, Milinichik AZ, Verdi AC, Maddage CJ, Rybinski KA, Fernando S, Fernando D, Kuc M, Furuuchi K, Fang F, Uenaka T, Grasso L, Albone EF.

Mol Cancer Ther. 2018 Dec;17(12):2665-2675. doi: 10.1158/1535-7163.MCT-17-1215. Epub 2018 Sep 27.

PMID:
30262588
2.

The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Lin J, Spidel JL, Maddage CJ, Rybinski KA, Kennedy RP, Krauthauser CL, Park YC, Albone EF, Jacob S, Goserud MT, Martinez BP, Chao Q, Zhou Y, Nicolaides NC, Kline JB, Grasso L.

Cancer Biol Ther. 2013 Nov;14(11):1032-8. doi: 10.4161/cbt.26106. Epub 2013 Aug 28.

Supplemental Content

Loading ...
Support Center